| Title | Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Zimmer AS, Steinberg SM, Smart DDee, Gilbert MR, Armstrong TS, Burton E, Houston N, Biassou N, Gril B, Brastianos PK, Carter S, Lyden D, Lipkowitz S, Steeg PS |
| Journal | Future Oncol |
| Volume | 16 |
| Issue | 14 |
| Pagination | 899-909 |
| Date Published | 2020 May |
| ISSN | 1744-8301 |
| Abstract | Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967). |
| DOI | 10.2217/fon-2020-0094 |
| Custom 1 | |
| Alternate Journal | Future Oncol |
| PubMed ID | 32270710 |
| PubMed Central ID | PMC7270957 |